News | January 23, 2014

Drug-Coated Device Opens Peripheral Arteries, Dissolves

Six-month results of ESPRIT trial promising

Espirt Bioresorbable Vascular Scaffold BVS Peripheral Artery Disease PAD

January 23, 2014 – Six-month results of the ESPRIT trial suggest a bioresorbable drug-eluting scaffold is effective in opening blocked blood vessels in the legs and pelvis, as presented at the 26th annual International Symposium on Endovascular Therapy (ISET). 

The bioresorbable vascular scaffold (BVS) looks and works like a stent to open blocked arteries in the legs or pelvis, and the drug coating prevents restenosis. The BVS is called a scaffold rather than a stent because it is a temporary structure that naturally dissolves into the blood stream within 18 months to two years.

 
“We’re seeing zero restenosis in the first patients to receive the BVS in the peripheral arteries, the vast majority of whom suffered moderate to severe pain while walking prior to treatment and had very little to no pain after treatment,” said Johannes Lammer, M.D., professor of radiology and director of the Division of Cardiovascular and Interventional Radiology at the Medical University of Vienna, Austria. “The BVS…opens arteries and prevents restenosis, then resorbs into the blood stream so there are no stent breaks, no prolonged irritation or delayed in-stent restenosis and no interference with magnetic resonance imaging or surgery.”
 
In the study of the Esprit BVS, 35 patients were treated for blockages averaging about 3.5 cm. Four patients had blockages in the pelvic iliac arteries and 31 in the superficial femoral artery. Six months after treatment, all of the arteries in the 34 patients who were followed remained open, with the narrowing reduced from an average of 80 percent prior to treatment to 13 percent after treatment. 
 
Prior to treatment, 32 patients (91 percent) had moderate to severe pain while walking, and no patients were pain-free. Six months after treatment, 29 patients (85 percent) had no pain while walking, and only one (3 percent) had moderate pain.
 
The BVS is made of polylactide, which naturally resorbs in the blood stream and has been shown to be safe in other medical uses, such as for dissolving stitches. A version of the device has been used to treat blocked heart arteries.
 
For more information: www.iset.ge

Related Content

Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months
News | Peripheral Artery Disease (PAD) | July 02, 2018
The PQ Bypass Detour System showed promising 12-month durability for patients with extremely long blockages in the...
SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the...
SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease
News | Peripheral Artery Disease (PAD) | May 14, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and...
Critical Limb Ischemia Treatment Shows No Improvement at Three Months
News | Peripheral Artery Disease (PAD) | March 23, 2018
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound...
FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions
Technology | Peripheral Artery Disease (PAD) | February 20, 2018
Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug...
News | Peripheral Artery Disease (PAD) | December 29, 2017
December 29, 2017 — iVascular announced the release of the new Oceanus 14 Pro percutaneous transluminal angioplasty (
Overlay Init